Table 1.
Patients’ baseline characteristics before and after matching
| Before matching | Matched | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| TACE n=212 |
TACE-MWA n=50 |
P | TACE n=100 |
P | ||
| Gender | Male | 195 (92) | 43 (86) | 0.183a | 91 (91) | 0.350 |
| Female | 17 (8) | 7 (14) | 9 (9) | |||
|
| ||||||
| Age (years) | ≤55 | 83 (39) | 22 (44) | 0.529 | 42 (42) | 0.815 |
| >55 | 129 (61) | 28 (56) | 58 (58) | |||
|
| ||||||
| ALT (U/L) | ≤56 | 103 (49) | 27 (54) | 0.491 | 50 (50) | 0.644 |
| >56 | 109 (51) | 23 (46) | 50 (50) | |||
|
| ||||||
| AFP (ng/mL) | ≤25 | 78 (37) | 22 (44) | 0.345 | 41 (41) | 0.726 |
| >25 | 134 (63) | 28 (56) | 59 (59) | |||
|
| ||||||
| Child-Pugh score | A | 184 (87) | 46 (92) | 0.312 | 94 (94) | 0.732a |
| B | 28 (13) | 4 (8) | 6 (6) | |||
|
| ||||||
| Tumor size (mm) | ≤50 | 110 (52) | 36 (72) | 0.010 | 73 (73) | 0.897 |
| >50 | 102 (48) | 14 (28) | 27 (27) | |||
|
| ||||||
| Tumor number | ≤3 | 59 (28) | 23 (46) | 0.013 | 46 (46) | 1.000 |
| >3 | 153 (72) | 27 (54) | 54 (54) | |||
Data are presented as n (%).
TACE, transarterial chemoembolization; TACE-MWA, combination therapy of transarterial chemoembolization and microwave ablation; ALT, alanine aminotransferase; AFP, alpha-fetoprotein.
a
Fisher’s exact test was performed for expected cell count <5.b